Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 250 invasive Streptococcus pneumoniae isolates from France.
The aim of the study presented here was to evaluate the in vitro activity of faropenem, a new member of the penem class intended for oral administration, compared with 11 other antimicrobial agents against a large number of Streptococcus pneumoniae strains isolated from adults and children with bloodstream infections in France. The minimum inhibitory concentration of faropenem against 90% of the pediatric strains tested was generally one to two dilutions lower than the most potent beta-lactam agents (i.e., 0.5 micro g/ml for faropenem vs. 1 for amoxicillin, 1 for cefotaxime and 0.5 micro g/ml for ceftriaxone). Against the adult strains, only moxifloxacin had a MIC(90) value similar to faropenem (i.e., 0.25 micro g/ml for both agents). Faropenem seems to be a promising antimicrobial agent for the treatment of adult and pediatric Streptococcus pneumoniae infections.
Decousser
J W
JW
Department of Hospital Health, Centre Hospitalier de Versailles, 177 rue de Versailles, 78157 Le Chesnay Cedex, France. jwdecousser@ch-versailles.fr
Pina
P
P
Picot
F
F
Allouch
P Y
PY
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D004352:Drug Resistance, Microbial; D005602:France; D006801:Humans; D007223:Infant; D007769:Lactams / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011008:Pneumococcal Infections / Q000175:diagnosis / Q000188:drug therapy; D012494:Sampling Studies; D012680:Sensitivity and Specificity; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D007769:Lactams; D047090:beta-Lactams; C107057:fropenem